HOOKIPA Pharma to Join the H.C. Wainwright Conference
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a prominent player in the field of immunotherapy development, has announced that its management team will participate in a respected global investment conference. The H.C. Wainwright 26th Annual Global Investment Conference will take place over several days, offering a valuable opportunity for the company to connect with industry leaders and potential investors.
Engagement with Investors
During the event, Dr. Malte Peters, HOOKIPA's Chief Executive Officer, along with Terry Coelho, Executive Vice President and Chief Financial Officer, will be hosting one-on-one meetings with investors. This proactive approach enables HOOKIPA to share insights about its innovative programs and address any questions investors may have directly.
Key Activities at the Conference
A highlight for HOOKIPA at the conference will be Dr. Peters' participation in a Fireside Chat, scheduled for a specific day during the event. This chat presents an opportunity for open dialogue, allowing attendees to gain deeper insights into the company's vision, research advancements, and clinical trials aimed at addressing serious diseases.
Accessing the Webcast
Investors and interested individuals will have the chance to tune into the fireside chat via a live webcast. This format allows a wider audience to engage with the valuable insights shared by the management team. Additionally, archived versions of the webcast will be made available on HOOKIPA's website after the session, ensuring that those who are unable to attend live can still access the information shared.
Exploring HOOKIPA's Innovations
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is leading the way in developing groundbreaking immunotherapies through its proprietary arenavirus platform. This innovative approach aims to mobilize and enhance targeted T cell responses to prevent or combat serious illnesses. The company's technology includes both replicating and non-replicating strategies, designed to elicit strong responses from CD8+ T cells and neutralizing antibodies.
Research and Development Pipeline
HOOKIPA's extensive pipeline focuses on investigational arenaviral immunotherapies that target significant health challenges, including Human Papillomavirus (HPV) 16-positive cancers and KRAS-mutated cancers, among other undisclosed projects. Additionally, HOOKIPA is collaborating with the industry leader Gilead to pursue functional cures for Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV), showcasing its commitment to tackling major global health issues.
Discover More about HOOKIPA
For those interested in learning more about HOOKIPA, additional information is available on the company’s official website. The site offers insights into their research initiatives, clinical trials, and ongoing projects, reflecting HOOKIPA's dedication to transparency and investor relations.
Contact Information
For further inquiries regarding investment opportunities or updates about the company, Chuck Padala, Managing Director at LifeSci Advisors, is the designated contact for investors. He is available via email for any detailed discussions or concerns regarding HOOKIPA’s initiatives.
Frequently Asked Questions
What is the purpose of HOOKIPA Pharma's participation in the conference?
HOOKIPA Pharma aims to connect with investors, showcase its innovative immunotherapeutics, and explore potential collaborations.
Who from HOOKIPA Pharma will be attending the conference?
Dr. Malte Peters, CEO, and Terry Coelho, CFO, will represent HOOKIPA Pharma at the conference.
Will the conference sessions be accessible to the public?
Yes, sessions such as the Fireside Chat will be available via webcast, providing wider access to interested parties.
What is the focus of HOOKIPA’s research and development?
HOOKIPA focuses on developing immunotherapies that target specific cancers and aims to create functional cures for HBV and HIV.
How can investors get more information about HOOKIPA Pharma?
Investors can visit HOOKIPA's official website for comprehensive information about the company's pipeline, research, and updates.
